Bruchim Ilan, Ben-Harim Zipi, Piura Ettie, Haran Gabi, Fishman Ami
a Division of Gynecologic Oncology , Meir Medical Center , Kfar Saba , Israel.
b Sackler School of Medicine , Tel Aviv University , Tel Aviv , Israel.
J Chemother. 2016 Apr;28(2):129-34. doi: 10.1080/1120009X.2015.1115195. Epub 2016 Apr 19.
Two topotecan treatment schedules in patients with recurrent epithelial ovarian cancer were evaluated. Protocol A (21 days) was 1.5 mg/m(2)/day topotecan on days 1 through 5 of a 21-day cycle; Protocol B (weekly) 4 mg/m(2) on days 1, 8, and 15 of a 28-day cycle. Efficacy was determined by clinical exam, CT scan, and CA125 levels. Forty-three patients on Protocol A and 21 on Protocol B were evaluated. As second-line treatment, Protocol A response was 9/20 (45%). Response to Protocol B was 4/17 (23.5%; NS). As third line or more, the response on Protocols A and B together was only 3/27 (11%). High-grade haematological toxicity was reported in 12/43 (27.9%) on Protocol A and 1/21 (4.8%) on Protocol B (p = 0.04). There was no difference in progression-free-intervals between schedules in second-line treatment. The weekly protocol had lower severe haematological toxicity. Clinical response in third line or more was very low.
对复发性上皮性卵巢癌患者的两种拓扑替康治疗方案进行了评估。方案A（21天方案）为在21天周期的第1至5天给予拓扑替康1.5mg/m²/天；方案B（每周方案）为在28天周期的第1、8和15天给予4mg/m²。通过临床检查、CT扫描和CA125水平来确定疗效。对方案A的43例患者和方案B的21例患者进行了评估。作为二线治疗，方案A的缓解率为9/20（45%）。方案B的缓解率为4/17（23.5%；无显著性差异）。作为三线或更后线治疗，方案A和方案B的总缓解率仅为3/27（11%）。方案A中有12/43（27.9%）报告有重度血液学毒性，方案B中有1/21（4.8%）报告有重度血液学毒性（p = 0.04）。二线治疗中两种方案的无进展生存期无差异。每周方案的重度血液学毒性较低。三线或更后线治疗的临床缓解率非常低。
